CHEMO RESEARCH, S.L. – Trademark Portfolio
Entity Type: 03
CHEMO RESEARCH, S.L. holds 36 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 33 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 7 trademarks are registered and 9 are pending. Notable registered marks include ECOZA, SLYND, NUVETEST, LIKE NO OTHER, and MY PILL AND MORE. The owner is based in 28050 Madrid.
Quintanapalla 2, 4a planta
28050 Madrid , ES
Showing of trademarks Trademarks
Trademark Classifications
CHEMO RESEARCH, S.L.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does CHEMO RESEARCH, S.L. have?
CHEMO RESEARCH, S.L. has 36 U.S. trademarks filed with the USPTO. Of these, 7 registered, 9 pending, 13 abandoned, 3 cancelled.
What trademark classes does CHEMO RESEARCH, S.L. file in?
CHEMO RESEARCH, S.L. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CHEMO RESEARCH, S.L.'s most well-known trademarks?
CHEMO RESEARCH, S.L.'s registered trademark portfolio includes well-known marks such as ECOZA, SLYND, NUVETEST, LIKE NO OTHER, and MY PILL AND MORE. These are among 7 currently registered trademarks in the portfolio.
What is CHEMO RESEARCH, S.L.'s trademark registration success rate?
CHEMO RESEARCH, S.L. has a 30% trademark registration rate, with 7 out of 23 resolved applications resulting in successful registration. Currently, 9 applications are pending review.